20 million USD Series C+ round closed
April 20, 2023
uBriGene Biosciences Inc. has closed a 150 million CNY (20 million USD) Series C+ financing round. It was completed just half a year after uBriGene’s Series C funding in September 2022, when the company received hundreds of millions of CNY (tens to hundreds of millions of USD).
The funds will be used for the expansion of uBriGene’s global footprint, developing prospective key technologies, and enhancing its global-oriented CGT CDMO platform.
The goal of expanding global production capacity is to meet the needs of overseas market, fully exploit the team’s strengths and advantages, improve the manufacturing platforms based in the United States to better provide services for global customers.
Accelerating prospective development of key technologies at uBriGene’s global R&D centers to enhance their one-stop GCT CDMO platform, which includes six core technology platforms: plasmid production, viral vector production, cell therapy drug preparation, nucleic acid therapeutics, as well as process development and quality control. In addition, the funds will be used for disruptive and fundamental innovations, breakthrough innovations for CGT industrialization, cost and efficiency improvements, as well as the commercialization of biological therapeutics to benefit more patients in a quick, economical and effective manner.
“I am very grateful to shareholders, investors, and partners for their recognition, trust, and support, and to our team for their persistent efforts and hard work. For more than ten years, uBriGene has experienced and witnessed the development and rise of the CGT industry and has continued to grow from tackling challenges. With an abundance of knowledge and experience accumulated, uBriGene has become a core participant in the CGT CDMO industry and new drug research and development industries. In recent years, uBriGene has been favored by investors for its outstanding technological innovation, high-quality products, and a reputation of excellence.
Whether it is in 2022, which was known as the "frozen capital" year, or in 2023, when the CGT market gradually returns to normal, we have always been supported by stable capital flow, which is the key to realizing the long-term strategic goal for uBriGene. The C+ round of financing will be mainly used to accelerate the internationalization of the company as well as to construct and improve the global CGT CDMO platform. With our continuous, fundamental innovations on technology, high-quality and cost-effective products, as well as comprehensive one-stop service capabilities, we will further open overseas markets and provide all-round assistance for global CGT pharmaceuticals in R&D, production, IND, and clinical trials as “a world-class cell & gene therapy CDMO partner, from concept to commercialization”.
October 2019: uBriGene raised tens of millions CNY (millions of USD) in angel round financing, which was used to improve and strengthen uBriGene CDMO team structure and equipment upgrades.
December 2020: uBriGene raised 120 million CNY (17 million USD) capital in Round A financing, which was used to improve the development of new vector technologies and platform processes, and comprehensively enhance the GMP-grade viral vectors production capacity.
September 2021: uBriGene raised nearly 200 million CNY (29 million USD) capital in Round B financing, which was used to improve viral vector manufacturing technologies, to expand the company's leading advantages in plasmids and AAV, to construct domestic and overseas commercial manufacturing facilities, to strengthen uBriGene’s market presence, as well as to reinforce its leading edge and to promote the development of the industry.
September 2022: uBriGene raised hundreds of millions of CNY (tens to hundreds of USD) in Round C finance, which was primarily allocated for the expansion of our global presence, establishing our Regional Headquarters in Vancouver Canada, and CMC R&D centers in United States, while further propelling the advancement and innovation of CGT technologies and processes, to continuously improve uBriGene's leading edge as a one-stop service provider in the field of CGT CDMO, to comprehensively scale up the production capacity of GMP AAV, plasmid, lentivirus, adenovirus, CAR-T, iPSC and nucleic acid therapeutics, to empower the development of new CGT drugs in China and globally, as well as to lead and to transform the industry.
April 2023: uBriGene raised 150 million CNY (20 million USD) in Round C+ of financing, which will be used to further accelerate the expansion of uBriGene’s global footprint, developing prospective key technologies, and enhancing its global-oriented CGT CDMO platform.
uBriGene Biosciences Inc. is dedicated to providing one-stop viral vector-based CDMO services for research and clinical applications. It has established integrated innovative biologics CDMO platforms that provide GMP-level plasmid preparation, viral packaging, and T-cell production services for large-scale CAR-T productions.
In addition, the company also provides viral vectors, including adenoviral and lentiviral vectors to meet the demands of research and/or manufacturing applications.
With its fermentation capacity ranging from 5L to 500L, uBriGene offers a versatile selection of research-grade, GMP-ready, or GMP-grade plasmids for research and clinical applications respectively.
uBriGene has an established global footprint with two GMP manufacturing facilities in China and Regional Headquarters in Vancouver, Canada. The newly acquired state-of-the-art facility in greater Boston area, has the GMP manufacturing capacity to serve the cell and gene therapies, as well as providing contract analytical services.